CAR T-cells for the treatment of bone metastatic cancer
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsDaniel Abate-Daga, Ismahéne Benzaid, Conor C. Lynch
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide.
Claims4
A method of providing an anti-cancer immunity in a subject with a bone metastatic cancer, the method comprising administering to the subject a recombinant T cell and a bisphosphonate,
- wherein the recombinant T cell expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide,
- wherein the CAR comprises a single-chain variable fragment (scFv) of an antibody that specifically binds prostate stem cell antigen (PSCA), a CD8 hinge and transmembrane domain, a CD3 zeta intracellular signaling domain, and a CD28 co-stimulatory signaling region.
Dependencies are inferred from the claim text.